# US 2024/0189436 A1 · BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189436 A1
- Document ID: US20240189436A1
- Status: Published application
- Kind: A1
- Application number: 18/499,739
- Filed: 2023-11-01
- Published: 2024-06-13
- Earliest claimed: 2017-12-19
- Assignees: BicycleTx Limited
- Applicants: BicycleTx Limited
- Inventors: Liuhong CHEN; Philip HUXLEY; Silvia PAVAN; Katerine VAN RIETSCHOTEN
- Web page: https://patentgrep.com/patent/US20240189436A1

## CPC

- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 38/05: Dipeptides
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

## Claims

### Claim 1

A method for synthesizing compound BCY6136:
or a salt thereof, the method comprising:
(1) providing compound 8:
or a salt thereof, and
(2) reacting compound 8, or the salt thereof, with compound BCY6099:
or a salt thereof, wherein Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said reaction is conducted in the presence of N,N-diisopropylethylamine (DIEA).

### Claim 3 (depends on 1)

The method according to claim 1, wherein said reaction is conducted in a solvent comprising dimethylacetamide (DMA).

### Claim 4 (depends on 1)

The method according to claim 1, further comprising:
(3) providing a polypeptide having an amino acid sequence: (β-Ala)-Sar10-(SEQ ID NO: 2)-CONH2; and
(4) reacting the polypeptide with 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA) to form compound BCY6099, or a salt thereof.

### Claim 5 (depends on 4)

The method according to claim 4, wherein reaction is conducted in a solvent comprising acetonitrile and water.

### Claim 6 (depends on 4)

The method according to claim 4, further comprising:
(5) synthesizing the polypeptide having the amino acid sequence: (β-Ala)-Sar10-(SEQ ID NO: 2)-CONH2 on a Rink Amide MBHA resin;
(6) treating the resin with a mixture comprising trifluoroacetic acid (TFA), triisopropylsilane (TIS), ethanedithiol (EDT), and H2O; and
(7) isolating the polypeptide from the mixture.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the mixture comprises about 92.5% TFA, about 2.5% TIS, about 2.5% EDT, and about 2.5% H2O.

### Claim 8

A method for synthesizing compound BCY6136:
or a salt thereof, the method comprising:
synthesizing a polypeptide having an amino acid sequence: (β-Ala)-Sar10-(SEQ ID NO: 2)-CONH2 on a Rink Amide MBHA resin, wherein Sar is sarcosine, HArg is homoarginine, and HyP is hydroxyproline;
treating the resin with a mixture comprising about 92.5% TFA, about 2.5% TIS, about 2.5% EDT, and about 2.5% H2O;
isolating the polypeptide from the mixture;
reacting the polypeptide with TATA in a solution comprising acetonitrile and water to form compound BCY6099:
or a salt thereof, and
reacting compound BCY6099, or a salt thereof, with compound 8:
or a salt thereof, in the presence of DIEA in a solvent comprising DMA to form compound BCY6136, or a salt thereof.
